HRP20130159T1 - Roskovitin, namijenjen lijeäśenju izvjesnih cistiäśnih bolesti - Google Patents
Roskovitin, namijenjen lijeäśenju izvjesnih cistiäśnih bolesti Download PDFInfo
- Publication number
- HRP20130159T1 HRP20130159T1 HRP20130159TT HRP20130159T HRP20130159T1 HR P20130159 T1 HRP20130159 T1 HR P20130159T1 HR P20130159T T HRP20130159T T HR P20130159TT HR P20130159 T HRP20130159 T HR P20130159T HR P20130159 T1 HRP20130159 T1 HR P20130159T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- intended
- disease
- kidney
- drug
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 4
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 6
- 201000002648 nephronophthisis Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 208000030761 polycystic kidney disease Diseases 0.000 claims 2
- 208000022330 Acquired cystic kidney disease Diseases 0.000 claims 1
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 1
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims 1
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000034946 Juvenile nephronophthisis Diseases 0.000 claims 1
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 201000001228 nephronophthisis 1 Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (7)
1. Spoj, ili njegova farmaceutski prihvatljiva sol, solvat ili hidrat, namijenjen upotrebi u postupku liječenja ili ublažavanja jednog ili više simptoma cistične bolesti, koju se bira između stečene cistične bolesti bubrega, cistične bolesti uzrokovane dijalizom, autosomno dominantne policistične bolesti bubrega, autosomno recesivne policistične bolesti bubrega, urođenog policističnog bubrega, policistično-displastičnog bubrega, završnog stadija bolesti bubrega, bubrega sa spužvastom medulom, kompleksa nefronoftize i medularne cistične bolesti bubrega, kompleks nefronoftize i uremične medularne cistične bolesti, juvenilne nefronoftize, medularne cistične bolesti, tuberozne skleroze i von Hippel-Lindauovog sindroma, naznačen time što spoj je 6-benzilamino-2-[(1-etil-2-hidroksi)etilamino]-9-izopropilpurin.
2. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što spoj je 6-benzilamino-2-(R)-[(1-etil-2-hidroksi)etilamino]-9-izopropilpurin.
3. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što spoj je 6-benzilamino-2-(S)-[(1-etil-2-hidroksi)etilamino]-9-izopropilpurin.
4. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što spoj je namijenjen primjeni u obliku pojedinačne doze.
5. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time
što spoj je namijenjen primjeni impulsnim doziranjem, ili
što spoj je namijenjen primjeni impulsnim doziranjem, koje se sastoji u primjeni spoja na subjektu tri tjedna uzastopno, za čim slijedi period od tri tjedna bez primjene lijeka; dva tjedna uzastopno, za čim slijedi period od dva tjedna bez primjene lijeka; 10 dana uzastopno, za čim slijedi period od 10 dana bez primjene lijeka; ili tjedan dana, za čim slijedi period od tjedan dana bez primjene lijeka.
6. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što cistična bolest je policistična bolest bubrega.
7. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što spoj je namijenjen oralnoj primjeni.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85276006P | 2006-10-19 | 2006-10-19 | |
| PCT/US2007/022389 WO2008051502A1 (en) | 2006-10-19 | 2007-10-19 | Purine derivatives for the treatment of cystic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130159T1 true HRP20130159T1 (hr) | 2013-03-31 |
Family
ID=38988354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130159TT HRP20130159T1 (hr) | 2006-10-19 | 2013-02-25 | Roskovitin, namijenjen lijeäśenju izvjesnih cistiäśnih bolesti |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20110046164A1 (hr) |
| EP (2) | EP2617423A1 (hr) |
| JP (2) | JP5550906B2 (hr) |
| DK (1) | DK2076268T3 (hr) |
| ES (1) | ES2402907T3 (hr) |
| HR (1) | HRP20130159T1 (hr) |
| PL (1) | PL2076268T3 (hr) |
| PT (1) | PT2076268E (hr) |
| RS (1) | RS52737B (hr) |
| SI (1) | SI2076268T1 (hr) |
| WO (1) | WO2008051502A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| EP2617423A1 (en) * | 2006-10-19 | 2013-07-24 | Genzyme Corporation | Purine derivatives for the treatment of cystic diseases |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2010103473A1 (en) | 2009-03-10 | 2010-09-16 | Chu De Brest | Method of treatment of polycystic diseases and chronic lymphocytic leukemia |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| US20200289482A1 (en) * | 2017-06-21 | 2020-09-17 | The Johns Hopkins University | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease |
| CN112794853B (zh) * | 2021-01-12 | 2021-11-30 | 江汉大学 | 一种有机硒化合物及其制备方法与应用 |
| CN112794852B (zh) * | 2021-01-12 | 2021-11-30 | 江汉大学 | 一种含硒有机化合物及其制备方法与应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5033352A (en) | 1989-01-19 | 1991-07-23 | Yamaha Corporation | Electronic musical instrument with frequency modulation |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| GB0017084D0 (en) * | 2000-07-13 | 2000-08-30 | Univ Bristol | Inhibition of the cystic fibrosis transmembrane conductance regulator chloride channel |
| US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| MXPA06012446A (es) * | 2004-04-29 | 2007-01-17 | Genzyme Corp | Metodos y composiciones para el tratamiento de enfermedades poliquisticas. |
| WO2006012310A2 (en) * | 2004-06-25 | 2006-02-02 | Genzyme Corporation | Carbazole derivatives for treating polycystic kidney disease |
| FR2876583B1 (fr) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| EP2617423A1 (en) * | 2006-10-19 | 2013-07-24 | Genzyme Corporation | Purine derivatives for the treatment of cystic diseases |
-
2007
- 2007-10-19 EP EP20130152163 patent/EP2617423A1/en not_active Withdrawn
- 2007-10-19 SI SI200731175T patent/SI2076268T1/sl unknown
- 2007-10-19 PT PT78528726T patent/PT2076268E/pt unknown
- 2007-10-19 ES ES07852872T patent/ES2402907T3/es active Active
- 2007-10-19 EP EP07852872A patent/EP2076268B1/en not_active Revoked
- 2007-10-19 RS RS20130141A patent/RS52737B/en unknown
- 2007-10-19 WO PCT/US2007/022389 patent/WO2008051502A1/en active Application Filing
- 2007-10-19 PL PL07852872T patent/PL2076268T3/pl unknown
- 2007-10-19 US US12/446,225 patent/US20110046164A1/en not_active Abandoned
- 2007-10-19 DK DK07852872.6T patent/DK2076268T3/da active
- 2007-10-19 JP JP2009533402A patent/JP5550906B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-25 HR HRP20130159TT patent/HRP20130159T1/hr unknown
-
2014
- 2014-03-10 US US14/203,010 patent/US20140249165A1/en not_active Abandoned
- 2014-05-21 JP JP2014104887A patent/JP2014169321A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20140249165A1 (en) | 2014-09-04 |
| WO2008051502A1 (en) | 2008-05-02 |
| EP2076268B1 (en) | 2013-01-23 |
| EP2617423A1 (en) | 2013-07-24 |
| DK2076268T3 (da) | 2013-04-22 |
| PL2076268T3 (pl) | 2013-06-28 |
| JP2014169321A (ja) | 2014-09-18 |
| ES2402907T3 (es) | 2013-05-10 |
| JP2010506938A (ja) | 2010-03-04 |
| US20110046164A1 (en) | 2011-02-24 |
| SI2076268T1 (sl) | 2013-04-30 |
| EP2076268A1 (en) | 2009-07-08 |
| PT2076268E (pt) | 2013-03-07 |
| RS52737B (en) | 2013-08-30 |
| JP5550906B2 (ja) | 2014-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130159T1 (hr) | Roskovitin, namijenjen lijeäśenju izvjesnih cistiäśnih bolesti | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| BRPI0518266A8 (pt) | Medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular | |
| JP2012515184A5 (hr) | ||
| JP2006502129A (ja) | 腎臓濾過および腎臓通過中のリソソーム分解に対して耐性を示す抗微生物性荷電ポリマー、その組成物および使用方法 | |
| JP2009269923A5 (hr) | ||
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| EA022840B1 (ru) | Фармацевтическая композиция, набор, их применение и способ профилактики и лечения симптома, состояния или заболевания, связанного с инфекцией вируса гриппа | |
| JP2015523395A5 (hr) | ||
| NO20082791L (no) | 6-fenyl-1H-imidazo[4,5-C]-pyridin-4-karbonitrilderivater som Cathepsin K- og S-inhibitorer | |
| NO20070146L (no) | 4-fenylpyrimidin-2-karbonitril-derivater | |
| RU2008110933A (ru) | Применение амброксола для лечения риновирусных инфекций | |
| JP2009506002A5 (hr) | ||
| ATE549015T1 (de) | Pharmazeutische wirkstoffhaltige formulierung mit überzug | |
| KR20100045513A (ko) | 감염의 치료 또는 제어를 위한, 퀴놀론을 포함하는 조성물 및 방법 | |
| JP2003246735A5 (hr) | ||
| BR0007473A (pt) | Composições tendo estabilidade melhorada | |
| EP1609473A8 (en) | Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria | |
| JP2012526099A5 (hr) | ||
| HRP20221185T1 (hr) | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom | |
| CA2641571A1 (en) | Treatment of osteoarthritis | |
| ITBZ20040044A1 (it) | Componente modulare per dispositivi per effettuare in un sistema di coordinate cartesiane la ricostruzione virtuale tridimensionale di superfici di corpi come pure un tale dispositivo comprendente una pluralita' di componenti modulari. | |
| WO2001012192A3 (en) | Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil |